PMC8068508_01
Radiological monitoring of the patient before and after treatment with sintilimab plus anlotinib. (A) Magnetic resonance imaging (MRI) was performed on the recurrence before treatment (Baseline), on May 16, 2019. (B and C). Computerized tomography (CT) on July 17, 2019 (B) and September 26, 2019 (C) showed the tumor shrank after 2 and 4 cycles of sintilimab-anlotinib, respectively. (D) CT on December 13, 2019 identified a little residue of the recurrence mass. (E) CT after 14.5 months of the treatment showed a sustained and prominent reduction of the tumor. (F) The tumor shrinkage was continued over 18.3 months as shown by the CT on November 24, 2020. The red arrow indicates tracheal compression, whereas the blue arrow indicates the tumor.
OTT-14-2741-g0001.jpg
PMC8068508_01_OTT-14-2741-g0001.jpg
f0001
Multiple metastatic lymph nodes were found in the bilateral neck, the biggest one about 1.6x1.0 cm (Figure 1A). Metastatic lymph nodes in the left neck were narrowed, with a short diameter shrinking from 1.0 cm to 0.7 cm in the largest one, and no swelling on the right side (Figure 1B). In addition, the mass continued to shrink with treatment (Figure 1C). Six months later, CT scan showed little remains with the MCSA of about 1.9x1.4 cm (Figure 1D). A follow-up CT scan at 14.5 months and 18.3 months after treatment demonstrated prominent and sustained reduction of the tumor (Figure 1E and F).